Calcitonin Gene-Related Peptide (CGRP) and Migraines is organized by College of Psychiatric and Neurologic Pharmacists (CPNP) and will be held from May 16, 2019 - Apr 09, 2022. This Course has been approved for a maximum of 1.0 Contact Hours.
This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
Migraine headaches are the most common neurologic problem of adults worldwide. Emerging theories on the pathophysiology of migraine pain and other symptoms will guide medication management in the future. One of the potential pathways for prophylaxis involves Calcitonin Gene-Related Peptide (CGRP) modulation. CGRPs represent a new medication management option with a novel mechanism of action for a disease state that hasn’t seen any changes since onabotulinumtoxinA was approved for the treatment of chronic migraine since 2010. Patients and prescribers rely on pharmacists to help select appropriate pharmacotherapy and provide education. Pharmacists should understand the CGRP pathway and the ways it may be modified to prevent migraines. This program will describe the current understanding of the pathophysiology of migraine, possible methods of intervening in this pathophysiology with CGRP modulators, and the potential place for CGRP modifying medications in migraine treatment.
You will proceed through the following steps to satisfactorily complete this course:
• Review the full content of the activity and reflect upon its teachings.
• Complete the post-test at the end of the activity no later than the closing activity date. (login first)
• Complete the evaluation at the end of the activity. (login first)
• If necessary, complete the post-test retest no later than the closing activity date. (login first)
• Receive a passing grade (70%).
• Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)
• Describe the trigeminovascular theory of migraine.
• Identify potential targets for intervention in the treatment or prevention of migraine, including methods of Calcitonin • Gene-Related Peptide (CGRP) modification.
• Evaluate the pros and cons of blocking CGRP in migraine patients.
• Discuss the potential place in pharmacotherapy for CGRP-modifying medications.
Additional details will be posted as soon as they are available.
Neurology, Molecular Biology